Clinical trials: Impairment, Cognitive
Early Alzheimers Disease
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen.
- Trial name
- NCT06709014
- Testing
- buntanetap/posiphen
- Where
- 78 sites in United States
- Volunteers
- 760 people
- Sponsor
- Annovis Bio Inc.
Alzheimer Disease, Mild Cognitive Impairment
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
Investigators propose a phase 1b/2a, randomized, double-blind, placebo-controlled, parallel group dose finding and biomarker study to evaluate the safety, tolerability, and biomarker activity of 2-HOBA in 48 MCI/AD participants.
- Trial name
- 2-HOBA (NCT06432166)
- Testing
- 2-hydroxybenzylamine acetate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- MTI Biotech Inc
Alzheimer Disease, Cognitive Impairment
The REMIND Study- SPARK Neuro Software Study
The study utilizes investigational software, the SPARK Test, with an FDA-cleared electroencephalography (EEG) amplifier and EEG cap to collect and patient EEG data.
- Trial name
- NCT05406778
- Testing
- SPARK Test
- Where
- 7 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Mild Cognitive Impairment
Efficacy and Safety Study of Shenwu Capsule
The purpose of this phase III study is to further evaluate the effects of shenwu capsule, a traditional Chinese herbal medicine, on cognition, function and memory in patients with amnestic mild cognitive impairment (MCI) who are…
- Trial name
- NCT01451749
- Testing
- Shenwu Capsule, Donepezil
- Where
- China
- Volunteers
- 324 people
- Sponsor
- North China Pharmaceutical Group Corporation
Mild Cognitive Impairment, Alzheimer's Disease
Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations
This is an open-label study to evaluate Aftobetin-HCl and florescence detection as measured by the Sapphire II device. Performance of Part I of the study has been completed (15 subjects received a single administration of…
- Trial name
- NCT02928211
- Testing
- Sapphire II, Aftobetin-HCl, Positron Emission Tomography
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Cognoptix, Inc.
Cognitive Dysfunction, Alzheimer's Disease
A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities
The primary objective of the study is to assess the safety impact of continuing aducanumab dosing in asymptomatic Amyloid-related Imaging Abnormalities (ARIA) in participants with mild cognitive impairment (MCI) due to…
- Trial name
- EVOLVE (NCT03639987)
- Testing
- Aducanumab
- Where
- 22 sites in United States
- Volunteers
- 52 people
- Sponsor
- Biogen
Schizophrenia, Alzheimer's Disease
The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients
This study in patients with stable schizophrenia will investigate the effect of JNJ-39393406 on Event Related Potentials (Auditory Evoked Potential [AEP] P50, AEP P300 and Mismatch Negativity [MMN]) after single dose…
- Conditions
- Schizophrenia, Alzheimer's Disease, Cognition Disorders
- Trial name
- NCT01137799
- Testing
- JNJ-39393406
- Where
- 4 sites in Germany
- Volunteers
- 47 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Aging, Cognitive Change
Test and Usability of Mixed-reality Screening Tool for Early Detection of Cognitive Declines
The aim of this study as part of the SCOBES-AR project is to establish and test a protocol for implementation and usability of mixed reality-enhanced multidisciplinary screening tool for early detection of cognitive impairments…
- Trial name
- SCOBES-AR (NCT05403814)
- Testing
- observational screening procedure (no intervention)
- Where
- Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- FH Joanneum Gesellschaft mbH
Fragile X Syndrome, Behavior
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
Diverse symptomatology makes Fragile X Syndrome (FXS) difficult to treat, and currently there are no approved prevention or treatment methods for FXS.
- Conditions
- Fragile X Syndrome, Behavior, Cognitive Dysfunction
- Trial name
- NCT05832255
- Testing
- Psilocybin, 1.5 mg
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Nova Mentis Life Science Corp
Dementia Alzheimers
Feasibility Study of Game Technology in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
This study will test G:DATA, a simple computer game designed to diagnose Alzheimer's Disease, in three different groups of people, some of whom have Alzheimer's Disease.
- Trial name
- G:DATA (NCT06047340)
- Testing
- G:DATA, dementia screen videogame
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ascentys Ltd
Cognitive Impairment, Schizophrenia
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults
The purpose of this study is to determine if eltoprazine (as an adjunct to anti-psychotic medication) improves one or more aspects of cognitive impairment in adult schizophrenic patients.
- Trial name
- NCT01266174
- Testing
- Eltoprazine
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Amarantus BioScience Holdings, Inc.
Mild Cognitive Impairment
Effect of Nutritional Supplementation With Turmeric on the Cognitive Performance of Subjects With Metabolic Syndrome
The EPICURO study aims to demonstrate the beneficial effects of a 6-month dietary supplementation with an improved bioavailable turmeric (MERIVA®) on inflammatory, oxidative and metabolic parameters together with cognitive…
- Trial name
- EPICURO (NCT04705220)
- Testing
- MERIVA® Tablets
- Where
- Italy
- Volunteers
- 85 people
- Sponsor
- Indena S.p.A
Parkinson Disease, Cognitive Dysfunction
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
- Trial name
- NCT05318937
- Testing
- SAGE-718
- Where
- 38 sites in United States
- Volunteers
- 86 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Major Depressive Disorder
Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)
The purpose of this study is to evaluate the effects of videogame-like digital therapies as adjunct therapy to antidepressant medications on cognitive deficits associated with major depressive disorder.
- Trial name
- NCT03310281
- Testing
- HOLD: Videogame
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Akili Interactive Labs, Inc.
Cognitive Disorder
A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects
The purpose of the study is to evaluate the effect of food, gender, and age on the single-dose pharmacokinetics (PK) of SUVN-D4010.
- Trial name
- NCT03031574
- Testing
- SUVN-D4010
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Schizophrenia
A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia
The primary objective of this protocol is to assess the efficacy of two dose strengths of varenicline (0.5 mg BID and 1mg BID) as adjunctive treatment for cognitive impairment in symptomatically stable outpatient schizophrenic…
- Trial name
- NCT00743847
- Testing
- varenicline
- Sponsor
- Pfizer
Age-related Functional Decline, Mild Cognitive Impairment
Health Benefits of Nutraceutical Supplementation in Older Adults.
This study examines a multi-ingredient nutraceutical designed to support several areas of health in older adults, including muscle strength, cognitive function, immune response, and inflammation.
- Trial name
- NCT07534878
- Testing
- Powder containing whey isolate and herbal extracts (30g sachet)
- Where
- India
- Volunteers
- 23 people
- Sponsor
- GPLIFE HEALTHCARE PRIVATE LIMITED
Cognition
Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment
The objective of this randomized, triple-blind, placebo-controlled clinical trial is to compare NANO-PSO therapy against placebo in improving cognitive abilities in older adults with mild to moderate non-vascular cognitive…
- Trial name
- COGMEG5 (NCT06520878)
- Testing
- NANO-PSO (pomegranate seed oil)
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Distribuidora Biolife SA de CV
Dementia, Alzheimer Disease 1
Study of APH-1105 in Patients With Mild to Moderate Alzheimer's Disease
This is a Phase 2 study assessing the safety, tolerability and efficacy of intranasal delivery of APH-1105 for the treatment of mild to moderate Alzheimer's in adult.
- Conditions
- Dementia, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3
- Trial name
- NCT03806478
- Testing
- APH-1105
- Volunteers
- 60 people
- Sponsor
- Aphios